303 related articles for article (PubMed ID: 30045050)
1. Management of dabigatran after overdosage: two case reports and suggestions for monitoring.
Billoir P; Girault C; Barbay V; Boyer D; Grangé S; Fresel M; Chrétien MH; Le Cam Duchez V
Blood Coagul Fibrinolysis; 2018 Nov; 29(7):653-655. PubMed ID: 30045050
[TBL] [Abstract][Full Text] [Related]
2. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
4. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab for dabigatran overdose in a child.
Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
[No Abstract] [Full Text] [Related]
7. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
[TBL] [Abstract][Full Text] [Related]
8. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
9. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
[TBL] [Abstract][Full Text] [Related]
10. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
Honickel M; Braunschweig T; Rossaint R; Stoppe C; Ten Cate H; Grottke O
Anesthesiology; 2017 Nov; 127(5):852-861. PubMed ID: 28857806
[TBL] [Abstract][Full Text] [Related]
11. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab for dabigatran overdose.
Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
[TBL] [Abstract][Full Text] [Related]
13. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
15. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Giustozzi M; Verso M; Agnelli G; Becattini C
J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
17. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of severe dabigatran intoxication with idarucizumab in a patient with acute kidney injury].
Poulsen CG; Bestle M; Boesby L
Ugeskr Laeger; 2017 Feb; 179(7):. PubMed ID: 28397672
[TBL] [Abstract][Full Text] [Related]
19. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study.
Schulman S; Ritchie B; Nahirniak S; Gross PL; Carrier M; Majeed A; Hwang HG; Zondag M;
Thromb Res; 2017 Apr; 152():44-48. PubMed ID: 28222322
[TBL] [Abstract][Full Text] [Related]
20. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
